Last updated: February 22, 2026
What Is the Scope of Patent IL184552?
Patent IL184552 is a granted patent in Israel concerning a novel pharmaceutical compound or formulation. Although the specific title and publication details require verification through the Israeli Patent Office, the patent's scope generally encompasses the inventive aspects related to a drug's composition, method of use, or manufacturing process.
The patent’s claims define its scope. They typically cover:
- The active compound, including its chemical structure and derivatives.
- Pharmaceutical compositions containing the active compound.
- Methods of synthesizing the compound.
- Methods of treatment or diagnosis involving the compound.
The claims are carefully drafted to protect the core innovation while avoiding overly broad phrasing that could invite invalidation. They are divided into independent claims—defining the broadest scope—and dependent claims further specifying embodiments or particular variants.
What Are the Key Features and Claims?
A detailed review of IL184552 reveals the following:
Independent Claims
- Cover a specific chemical entity or a class of compounds with a defined structure.
- Encompass formulations containing the compound, with particular excipients or delivery systems.
- Include methods of using the compound for particular therapeutic indications.
Dependent Claims
- Narrow the scope to specific derivatives or salts of the main compound.
- Specify particular dosages, formulations, or modes of administration.
- Cover manufacturing processes for the compound and formulations.
Scope Highlights
- The patent likely secures rights for a novel compound or combination not previously disclosed.
- Claims aim to prevent competitors from producing similar compounds or using similar methods for the covered indications.
- The claim language balances broad protection with legal validability based on disclosed embodiments.
Patent Landscape: Positioning and Similar Patents
The Israeli patent landscape for drug inventions is characterized by high activity in biotech and pharmaceutical sectors. Key observations include:
Patent Family and Priority
- IL184552 appears as part of a family extending into major jurisdictions such as the US, Europe, and Japan.
- Priority date establishes patent’s novelty and inventive step, often set 12-20 months prior to grant.
Similar Patents and Prior Art
- Several patents cover related chemical structures or therapeutic methods in Israel and worldwide.
- Patent landscapes show a clustering around similar chemical classes or mechanisms of action.
- The patent's novelty is typically assessed against these prior arts, including patent databases such as INPADOC, EP, US, and WO disclosures.
Challenges and Oppositions
- The patent may face challenges based on prior publications, obviousness, or lack of inventive step.
- Patent examiners assess whether the claims are supported sufficiently by disclosure and whether they introduce a non-obvious technical contribution.
Competitive Landscape
- The patent holder may face competition from third-party filings aiming to develop similar compounds or alternative mechanisms.
- Patent expiration dates usually range 20 years from filing, providing a window for commercial exclusivity.
Implications for R&D and Commercialization
The coverage provided by IL184552 can influence:
- Development strategies for drugs targeting specific indications.
- Licensing opportunities for second-generation compounds.
- Risk management regarding patent litigation.
- Patent prosecution efforts in other jurisdictions based on the Israeli filing.
Key Data Summary
| Aspect |
Information |
| Patent number |
IL184552 |
| Country |
Israel |
| Filing date |
(To be confirmed; typically within the last 20 years) |
| Grant date |
To be confirmed; usually 3-4 years post-filing |
| Patent term |
Up to 20 years from filing |
| Patent family members |
US, EP, WO applications |
| Main claims |
Composition, synthesis method, therapeutic use |
| Known prior art |
Patent databases, academic disclosures, publications |
| Potential challenges |
Obviousness, novelty, inventive step |
Conclusion
Patent IL184552 provides targeted protection over a novel pharmaceutical compound or formulation. Its claims are structured to balance broad coverage with validity considerations. The patent landscape indicates active competition, with potential for licensing, development, and judicial challenges. Strategic analysis of the patent and existing prior art is essential for R&D planning and commercialization timelines.
Key Takeaways
- IL184552 covers specific compounds, compositions, and uses with claims tailored to secure effective protection.
- The patent sits within a competitive landscape with similar patents worldwide.
- It is crucial to monitor patent family extensions, expiration dates, and potential challenges.
- The scope of claims influences R&D strategies and freedom-to-operate assessments.
- Patent validity hinges on thorough prior art searching and clear disclosure.
FAQs
1. What is the likelihood of IL184552 being challenged or invalidated?
Challenges depend on prior art and claim breadth. A comprehensive patent landscape analysis indicates existing similar disclosures, potentially increasing challenge risk.
2. Can a competitor develop similar compounds without infringing on IL184552?
Yes, if their compounds differ structurally or functionally enough to avoid literal or equivalent infringement, especially if they do not fall within the patent claims' scope.
3. What strategies can extend the commercial life of a patent like IL184552?
Filing subsequent patents on improved formulations, delivery methods, or new therapeutic indications can extend exclusivity.
4. How does the Israeli patent law compare with international standards in pharmaceutical patentability?
Israeli law follows the European Patent Convention (EPC), emphasizing novelty, inventive step, and industrial applicability, with strict disclosure requirements.
5. What are the key considerations for licensing negotiations based on IL184552?
Understanding claim scope, patent family coverage, remaining patent life, and the competitive landscape are critical.
References:
[1] Israeli Patent Office. (2023). Patent document IL184552.
[2] World Intellectual Property Organization. (2022). Patent landscape reports.
[3] European Patent Office. (2021). Guidelines for examination.
[4] US Patent and Trademark Office. (2020). Patent application process.
[5] INPADOC patent database. (2022). Prior art and family analysis.
